Although some outcomes showed small to medium effect sizes, these results must be interpreted cautiously given the presence of uncertainty factors, including considerable heterogeneity and moderate ...

Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated ...

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory ...

Background Eisenmenger syndrome (ES) is a severe and fatal complication of uncorrected congenital heart disease characterised ...

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia) delivered sustained ...

PACS announced operating results for the third quarter of 2025. PACS has completed its Restatement of financials and is ...

The gene therapy market for ocular rare diseases is expanding rapidly as breakthroughs in viral vectors (like AAV) and gene-editing tools enable one-time, disease-modifying treatments for previously ...

The owner of LED-light therapy mask CurrentBody--which listed on the London Stock Exchange last month--on Wednesday attributed its performance to an ever-increasing awareness of the at-home ...